References
The End of Alzheimer’s Program – Dale E. Bredesen, M.D. References
Following is a list of references from the book, The End of Alzheimer’s Program, published by Avery/Random House. Due to the length of the text, these references could not be included in the print version, and therefore are listed below.
87 – US Food and Drug Administration, last modified January 19, 2016
FDA Drug Safety Communication: Important Safety Label Changes to Cholesterol-Lowering Statin Drugs
88 – Yoshiaki Sato et al., Journal of Lipid Research 53, no. 3, 567–76, December 2011
Identification of a New Plasma Biomarker of Alzheimer’s Disease Using Metabolomics Technology
89 – Pollin and Quartuccio,
What We Know About Diet
90 – Alina Solomon et al., Dementia and Geriatric Cognitive Disorders 28, no. 1, 75–80, August 2009
Midlife Serum Cholesterol and Increased Risk of Alzheimer’s and Vascular Dementia Three Decades Later
90 – Michelle M. Mielke et al., Neurology 75, no. 21, 1888–95, November 2010
The 32-Year Relationship Between Cholesterol and Dementia from Midlife to Late Life
90 – Peter van Vliet, Journal of Alzheimer’s Disease 30, supplement 2, S147–62, January 2012
Cholesterol and Late-Life Cognitive Decline
90 – Jeremy M. Silverman and James Schmeidler, Alzheimer’s and Dementia 14, no. 7, 952–60, March 2018
Outcome Age-Based Prediction of Successful Cognitive Aging by Total Cholesterol
91 – Hack-Lyoung Kim and Sang-Hyun Kim, Frontiers in Cardiovascular Medicine 6, 41, April 2019
Pulse Wave Velocity in Atherosclerosis
91 – Laure Rouch et al., Hypertension 72, no. 5, 1109–16, November 2018